

## Novel synthesis and biological activity study of pyrimido[2,1-*b*] benzothiazoles

Shikha Gupta<sup>a\*</sup>, Neha Ajmera<sup>a</sup>, Naveen Gautam<sup>b</sup>, Rajni Sharma<sup>c</sup> & D C Gautam<sup>a</sup>

<sup>a</sup>Department of Chemistry, University of Rajasthan, Jaipur 302 004, India

<sup>b</sup>Department of Chemistry, L.B.S. Govt. P.G. College, Kotputli, Jaipur 303 108, India

<sup>c</sup>Department of Microbiology, S.M.S. Medical College, Jaipur, India

E-mail : shikha\_urj@yahoo.com

Received 14 July 2008; accepted (revised) 3 February 2009

A convenient and apparently simple procedure has been developed to prepare a series of substituted pyrimido [2,1-*b*]benzothiazoles by the conjugate addition of the imino nitrogen of 2-aminobenzothiazoles to alkyne  $\beta$ -carbon atom of acetylenic acid followed by ring closure. They are screened for antimicrobial activity and found to exhibit significant activities.

**Keywords:** Michael addition, fused nitrogen heterocycles, cyclocondensation

Condensed pyrimidine compounds<sup>1-13</sup> are reported to possess interesting pharmacological properties such as antibacterial, antifungal etc. As a part of an ongoing study of the synthesis of heterocyclic compounds of potential biological activity from allenic and acetylenic compounds<sup>14,15</sup>, a series of substituted pyrimido[2,1-*b*]benzothiazoles are synthesized. The results of these studies along with the antimicrobial activities of these compounds are reported in this paper. The structure of these compounds are determined on the basis of their spectral data and elemental analysis (**Tables I and II**).

### Results and Discussion

The conjugate addition of the imino nitrogen of 2-aminobenzothiazole **1** to the alkyne  $\beta$ -carbon atom of acetylenic acids **2** in butanol followed by cyclocondensation, gave the corresponding 2*H*-pyrimido[2,1-*b*]benzothiazol-2-ones **6,7** in 59-75% yield (**Scheme I**).

The structures of these compounds were determined by <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra (**Table II**).

When 2-aminobenzothiazoles **1a-1e** were allowed to react with phenyl propiolic acid **2a**, 4-phenyl-2*H*-pyrimido[2,1-*b*]benzothiazol-2-ones **6a-e** were obtained. The NMR spectra of the 8-chloro compound **6a** and 8,9-dimethyl compound **6c** showed singlets at  $\delta$  6.20 and  $\delta$  6.19, respectively, attributed to 3-H and

doublets at  $\delta$  6.04 and  $\delta$  5.75, respectively, for 6-H. The shielding effects observed for the 6-H in the compounds **6a-c** is due to the diamagnetic effect of the phenyl group attached to C-4. The above data exclude the formation of the isomeric 2-phenyl-4*H*-pyrimido[2,1-*b*]benzothiazole-4-ones **8** which should exhibit a deshielded proton (6-H) near  $\delta$  9.00 resulting from the anisotropic effect of the carbonyl group. Further evidence for the formation of the 2-one derivatives was obtained from the fact that no shielding effect was noticed in compounds **7a-e** where phenyl group was replaced by 1-pentyl respectively.

The reaction of 2-aminobenzothiazoles **1** with acetylenic acids **2** is rationalized as shown (**Scheme I**), where the alkynoic acid is first attacked at the  $\beta$ -carbon atom by the ring nitrogen atom of the benzothiazole. An attack of the 2-amino group of **1** on the  $\beta$ -carbon of **2** which eventually would generate the isomeric product **8** definitely does not occur<sup>16,17</sup> (**Scheme II**).

### Experimental Section

All the melting points were determined in open capillaries and are uncorrected. The purity of compounds was checked by TLC on silica gel G coated glass plates. IR spectra were recorded in KBr on a Shimadzu FT-IR 8400 spectrophotometer, <sup>1</sup>H and <sup>13</sup>C NMR in CDCl<sub>3</sub> were recorded on a JEOL AL-300 using TMS as internal standard. Mass

**Table I** — Characterization data of compounds **6**, **7a-e**

Compd	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	m.p. (°C)	Yield (%)	Mol. Formula	Found (Calcd) (%)			
									C	H	N	
<b>6a</b>	H	Cl	H	H	Ph	78	62	C <sub>16</sub> H <sub>9</sub> N <sub>2</sub> OSCl	61.51 (61.44)	2.86 2.88	8.92 8.96)	
<b>6b</b>	H	H	Br	H	Ph	61	69	C <sub>16</sub> H <sub>9</sub> N <sub>2</sub> OSBr	53.99 (53.78)	2.48 2.52	7.77 7.84)	
<b>6c</b>	Me	Me	H	H	Ph	62	70	C <sub>18</sub> H <sub>14</sub> N <sub>2</sub> OS	70.65 (70.58)	4.56 4.57	9.12 9.15)	
<b>6d</b>	H	Me	H	Me	Ph	160	74	C <sub>18</sub> H <sub>14</sub> N <sub>2</sub> OS	70.46 (70.58)	4.55 4.57	9.17 9.15)	
<b>6e</b>	H	Cyclic C <sub>4</sub> H <sub>4</sub> -bonded at C-7 and C-8 position			H	Ph	49	67	C <sub>20</sub> H <sub>13</sub> N <sub>2</sub> OS	72.90 (72.94)	3.92 3.95	8.47 8.51)
<b>7a</b>	H	Cl	H	H	1-pentyl	48	59	C <sub>15</sub> H <sub>15</sub> N <sub>2</sub> OSCl	58.89 (58.72)	4.91 4.89	9.11 9.13)	
<b>7b</b>	H	H	Br	H	1-pentyl	80	72	C <sub>15</sub> H <sub>15</sub> N <sub>2</sub> OSBr	51.40 (51.28)	4.25 4.27	7.92 7.97)	
<b>7c</b>	Me	Me	H	H	1-pentyl	85	72	C <sub>17</sub> H <sub>20</sub> N <sub>2</sub> OS	68.32 (68.00)	6.62 6.66	9.31 9.33)	
<b>7d</b>	H	Me	H	Me	1-pentyl	80	75	C <sub>17</sub> H <sub>20</sub> N <sub>2</sub> OS	67.94 (68.00)	6.61 6.66	9.30 9.33)	
<b>7e</b>	H	Cyclic C <sub>4</sub> H <sub>4</sub> -bonded at C-7 and C-8 position			H	1-pentyl	51	68	C <sub>19</sub> H <sub>19</sub> N <sub>2</sub> OS	70.70 (70.58)	5.85 5.88	8.61 8.66)

**Table II** — Spectral data of compounds **6**, **7a-e**

Compd	<sup>1</sup> H NMR (δ, ppm)	<sup>13</sup> C NMR (δ, ppm)	Mass <i>m/z</i> (%)	IR ν (cm <sup>-1</sup> )
<b>6a</b>	6.04 (1H, d, 6-H), 6.20 (1H, s, 3-H), 7.21 (1H, dd, 7-H), 7.9 (1H, s, 9-H), 7.5 (2H, d, 2'-H, 6'-H), 7.71 (2H, dd, 3'-H, 5'-H), 7.64 (1H, dd, 4'-H)	117.2 (C-6), 126.1 (C-7), 132.4 (C-8), 123.0 (C-9), 133 (C-5a), 124.9 (C-9a), 163.0 (C-10a), 166.7 (C-2), 99.6 (C-3), 149.0 (C-4), 128.5 (C-2', C-6'), 129.6 (C-3', C-5'), 130.9 (C-4'), 131.9 (C-1')	312.54 (M <sup>+</sup> , 74%), 314.5 (M+2, 25%), 284 (34%), 277 (15%), 275 (39%), 271 (45%), 210 (20%), 182 (100%) etc.	1650 (C=O), 1612 (C=N), 1590 (C=C)
<b>6b</b>	6.14 (1H, s, 6-H), 6.10 (1H, s, 3-H), 7.32 (1H, dd, 8-H), 7.84 (1H, d, 9-H), 7.49 (2H, d, 2'-H, 6'-H), 7.65 (2H, dd, 3'-H, 5'-H), 7.62 (1H, dd, 4'-H)	119.6 (C-6), 120.5 (C-7), 129.4 (C-8), 125.0 (C-9), 122.9 (C-9a), 137.2 (C-5a), 164.9 (C-10a), 167.0 (C-2), 99.7 (C-3), 149.2 (C-4), 128.3 (C-2', C-6'), 129.5 (C-3', C-5'), 130.8 (C-4'), 131.7 (C-1')	357 (M <sup>+</sup> , 50%), 359 (M+2, 49%), 328 (78%), 315 (42%), 277 (100%), 275 (25%), 254 (20%), 226 (10%) etc.	1645 (C=O), 1605 (C=N), 1585 (C=C)
<b>6c</b>	1.89 (3H, s, 8-CH <sub>3</sub> ), 2.18 (3H, s, 9-CH <sub>3</sub> ), 5.75 (1H, d, 6-H), 6.19 (1H, s, 3-H), 6.9 (1H, d, 7-H), 7.37 (2H, d, 2'-H, 6'-H), 7.53 (2H, dd, 3'-H, 5'-H), 7.60 (1H, dd, 4'-H)	113.2 (C-6), 126.5 (C-7), 136.0 (C-8), 132.8 (C-9), 124.5 (C-9a), 132.0 (C-5a), 164.8 (C-10a), 19.4 (8-CH <sub>3</sub> ), 20.0 (9-CH <sub>3</sub> ), 167.1 (C-2), 112.7 (C-3), 148.8 (C-4), 128.3 (C-2', C-6'), 129.1 (C-3', C-5'), 130.6 (C-4'), 132.0 (C-1')	306 (M <sup>+</sup> , 100%), 278 (52%), 265 (10%), 204 (49%), 189 (14%) etc.	1635 (C=O), 1600 (C=N), 1565 (C=C)
<b>6d</b>	1.81 (3H, s, 6-CH <sub>3</sub> ), 1.91 (3H, s, 8-CH <sub>3</sub> ), 6.92 (1H, d, 7-H), 7.36 (1H, d, 9-H), 6.21 (1H, s, 3-H), 7.35 (2H, d, 2'-H, 6'-H), 7.55 (2H, dd, 3'-H, 5'-H), 7.61 (1H, dd, 4'-H)	125.4 (C-6), 127.3 (C-7), 135.2 (C-8), 120.6 (C-9), 123.7 (C-9a), 121.7 (C-5a), 165.0 (C-10a), 167.2 (C-2), 112.6 (C-3), 148.9 (C-4), 128.2 (C-2', C-6'), 129.0 (C-3', C-5'), 130.8 (C-4'), 131.6 (C-1'), 18.0 (6-CH <sub>3</sub> ), 19.4 (8-CH <sub>3</sub> )	306 (M <sup>+</sup> , 100%), 278 (53%), 265 (7%), 204 (50%), 189 (12%) etc.	1640 (C=O), 1600 (C=N), 1568 (C=C)

—Contd

**Table II** — Spectral data of compounds **6**, **7a-e** — *Contd*

Compd	<sup>1</sup> H NMR (δ, ppm)	<sup>13</sup> C NMR (δ, ppm)	Mass <i>m/z</i> (%)	IR ν (cm <sup>-1</sup> )
<b>6e</b>	6.84 (1H, s, 6-H), 7.61 (1H, dd, 7-H), 7.30 (1H, dd, 8-H), 7.31 (1H, dd, 9-H), 7.66 (1H, d, 10-H), 7.00 (1H, s, 11-H), 5.68 (1H, s, 3-H), 7.30 (2H, d, 2'-H, 6'-H), 7.21 (2H, dd, 3'-H, 5'-H), 7.14 (1H, dd, 4'-H)	119 (C-6), 131 (C-6a), 128.3 (C-7), 125.6 (C-8), 124.6 (C-9), 126.2 (C-10), 123.7 (C-10a), 126.9 (C-11), 135.7 (C-11a), 132.6 (C-5a), 167.8 (C-12a), 163.0 (C-2), 99.8 (C-3), 150.2 (C-4), 128.2 (C-2', C-6'), 128.4 (C-3', C-5'), 128.4, 127.7 (C-4'), 134.9 (C-1')	329 (M <sup>+</sup> , 100%), 301 (38%), 288 (51%), 277 (20%), 199 (18%) etc.	1640 (C=O), 1590 (C=N), 1570 (C=C)
<b>7a</b>	7.59 (1H, d, 6-H), 6.13 (1H, s, 3-H), 7.62 (1H, dd, 7-H), 7.74 (1H, s, 9-H), 3.02 (2H, t, 1'-H), 1.75 (2H, tt, 2'-H), 1.51 (2H, m, 3'-H), 1.42 (2H, m, 4'-H), 0.95 (3H, t, 5'-H)	117 (C-6), 126.2 (C-7), 133.3 (C-8), 123.3 (C-9), 133.6 (C-5a), 125.1 (C-9a), 164.8 (C-10a), 167.2 (C-2), 110.7 (C-3), 151.5 (C-4), 13.8 (C-5'), 22.5 (C-4'), 26.8 (C-2'), 31.2 (C-3'), 33.5 (C-1')	306.52 (M <sup>+</sup> , 75%), 308.5 (M+2, 24%), 271 (20%), 269 (16%), 264 (39%), 250 (54%), 222 (43%), 210 (100%) etc.	1648 (C=O), 1584 (C=N), 1520 (C=C)
<b>7b</b>	6.15 (1H, s, 3-H), 7.62 (1H, s, 6-H), 7.56 (1H, dd, 8-H), 7.75 (1H, s, 9-H), 3.12 (2H, t, 1'-H), 1.70 (2H, tt, 2'-H), 1.50 (2H, m, 3'-H), 1.41 (2H, m, 4'-H) 0.92 (3H, t, 5'-H)	119.5 (C-6), 120.4 (C-7), 129.5 (C-8), 124.9 (C-9), 123.0 (C-9a), 137.0 (C-5a), 164.8 (C-10a), 167.1 (C-2), 110.5 (C-3), 151.4 (C-4), 13.9 (C-5'), 22.4 (C-4') 26.7 (C-2'), 31.2 (C-3'), 33.8 (C-1')	351 (M <sup>+</sup> , 50%), 353 (M+2, 48%), 308 (43%), 294 (28%), 271 (16%), 269 (12%), 254 (100%) etc.	1644 (C=O), 1580 (C=N), 1510 (C=C)
<b>7c</b>	2.28 (3H, s, 8-H), 2.32 (3H, s, 9-CH <sub>3</sub> ), 6.11 (1H, s, 3-H), 7.45 (1H, d, 6-H), 7.42 (1H, d, 7-H), 2.98 (2H, t, 1'-H), 1.71 (2H, tt, 2'-H), 1.43 (2H, m, 3'-H), 1.38 (2H, m, 4'-H), 0.88 (3H, t, 5'-H)	113.0 (C-6), 126.6 (C-7), 136.9 (C-8), 133.1 (C-9), 124.7 (C-9a), 132.6 (C-5a), 165 (C-10a), 167.3 (C-2), 110.6 (C-3), 151.3 (C-4), 33.5 (C-1'), 26.7 (C-2') 30.8 (C-3'), 22.1 (C-4'), 13.7 (C-5') 19.4 (CH <sub>3</sub> -8), 20.0 (CH <sub>3</sub> -9)	300 (M <sup>+</sup> , 100%), 258 (18%), 244 (15%), 216 (12%), 204 (28%) etc.	1640 (C=O), 1570 (C=N), 1500 (C=C)
<b>7d</b>	1.99 (3H, s, 6-CH <sub>3</sub> ), 2.30 (3H, s, 8-CH <sub>3</sub> ), 7.45 (1H, d, 7-H), 7.65 (1H, d, 9-H), 6.12 (1H, s, 3-H), 2.97 (2H, t, 1'-H), 1.72 (2H, tt, 2'-H), 1.41 (2H, m, 3'-H), 1.35 (2H, m, 4'-H), 0.91 (3H, t, 5'-H)	125.2 (C-6), 127.4 (C-7), 125.3 (C-8), 121.0 (C-9), 124.3 (C-9a), 133.4 (C-5a), 165.2 (C-10a), 167.0 (C-2), 110.5 (C-3), 151.0 (C-4), 33.2 (C-1'), 26.6 (C-2'), 30.9 (C-3'), 22.0 (C-4'), 13.6 (C-5'), 18.0 (CH <sub>3</sub> -68), 19.4 (CH <sub>3</sub> -8)	300 (M <sup>+</sup> , 100%), 258 (36%), 244 (39%), 216 (36%), 204 (85%) etc.	1645 (C=O), 1575 (C=N), 1510 (C=C)
<b>7e</b>	7.54 (1H, s, 6-H), 7.60 (1H, dd, 7-H), 7.32 (1H, dd, 8-H), 7.31 (1H, dd, 9-H), 7.62 (1H, d, 10-H), 7.02 (1H, s, 11-H), 5.62 (1H, s, 3H), 3.05 (2H, t, 1'-H), 1.72 (2H, tt, 2'-H), 1.50 (2H, m, 3'-H), 1.43 (2H, m, 4'-H), 0.92 (3H, t, 5'-H)	119.2 (C-6), 130.2 (C-6a), 128.1 (C-7), 125.9 (C-8), 123.8 (C-9), 125.4 (C-10), 122.8 (C-10a), 125.8 (C-11), 134.8 (C-11a), 131.8 (C-5a), 166.6 (C-12a), 163.8 (C-2), 103.6 (C-3), 149.8 (C-4), 13.5 (C-5'), 22.8 (C-4'), 26.9 (C-2'), 31.5 (C-3'), 33.8 (C-1')	323 (M <sup>+</sup> , 100%), 281 (38%), 267 (52%), 239 (45%), 227 (18%) etc.	1635 (C=O), 1578 (C=N), 1520 (C=C)


spectra were recorded on JEOL SX 102/DA-6000 using Argon/Xenon as FAB gas. All the compounds gave satisfactory elemental analysis.

#### Synthesis of 2H-pyrimido[2,1-*b*] benzothiazole-2-ones **6**, **7a-e**


The alkynoic acid **2a,b** (20 mmole) and the appropriate 2-amino benzothiazole (**1a-e**, 10 mmole) were heated to reflux in 1-butanol (50 mL) for 48 hr. Evaporation of solvent under reduced pressure gave the crude product which was crystallized from hexane/ethyl acetate to give the 2H-pyrimido [2,1-*b*] benzothiazol-2-ones.

#### Antimicrobial activity

The synthesized compounds were tested for their antibacterial activity by using Paper Disc method by measuring the zone of inhibition on agar plates with *Escherichia coli*, *Staphylococcus aureus*, *Enterobacter* as test organisms at concentration of 100 µg per disc using vancomycin and meropenem as standard compounds and antifungal activity against various strains of *Candida albicans* at concentration of 100 µg/disc using fluconazole as standard compound (**Table III**).



Scheme I



Scheme II

**Table III** — Antimicrobial activity of compounds **6**, **7a-e**

Compd	Antibacterial activity (Zone of inhibition in mm)			Antifungal activity (Zone of inhibition in mm)	
	<i>E. coli</i>	<i>Entero- bacter</i>	<i>Staphylococcus aureus</i>	<i>Candida albicans</i> strain 1	<i>Candida albicans</i> strain 2
<b>6a</b>	15	14	-	12	15
<b>6b</b>	11	12	-	10	10
<b>6c</b>	7	7	7	12	7
<b>6d</b>	12	13	14	11	12
<b>6e</b>	-	-	-	24	24
<b>7a</b>	-	7	7	32	36
<b>7b</b>	-	-	-	-	6
<b>7c</b>	14	15	8	-	7
<b>7d</b>	-	-	-	18	18
<b>7e</b>	-	-	13	20	21
Meropenem	16	16	16	-	-
Vancomycin	-	-	15	-	-
Flucanazole	-	-	-	25	25

Note: < 7mm, inactive; 7-9 mm weakly active;  
10-12 mm, moderately active; > 12 mm, active

< 7 mm, inactive; 7-11 mm, weakly active;  
12-17 mm, moderately active; > 17 mm, active

## Conclusion

It is evident that the synthesized compounds are biologically active. The results of antibacterial screening indicated that good activity was shown by compounds **6a,7c** against *E. coli* and *Enterobacter* and compound **6d,7e** against *Staphylococcus aureus*. Moderate activity was shown by compound **6b, 6d** against *E. coli* and *Enterobacter*. Other compounds showed less or no activity against all bacterial strains.

Regarding antifungal activity, compounds **6e,7a,7d,7e** showed good activity against strains of *Candida albicans*. Other compounds showed moderate to less activity against strains of *Candida albicans* (Table III).

## Acknowledgements

The authors are grateful to the Head, CDRI, Lucknow for providing spectral data. They are further grateful to S.M.S. Medical College, Jaipur for the biological activity of synthesized compounds.

## References

- Al Jallo H N & Muniem M A, *J Heterocycl Chem*, 15, **1978**, 849.
- Alamino R J, *J Heterocycl Chem*, 10, **1973**, 769.
- Dunwell D W & Evans D, *J Chem Soc*, **1971**, 2094.
- Santagati A, Santagati M & Russo F, *J Heterocycl Chem*, 25, **1988**, 949.
- Wade J J, Hegel R F & Toso C B, *J Org Chem*, 44, **1979**, 1811.
- Acheson R M & Wallis D J, *J Chem Soc, Perkin Trans 1*, **1982**, 1905.
- Doad G J S, Okor D & Schenmann F, *J Chem Soc Perkin Trans 1*, **1988**, 2993.
- Landreau C, Deniaud D, Evain M, Reliquet A & Meslin J C, *J Chem Soc, Perkin Trans 1*, **2002**, 741.
- Ai J, Wang X, Wahe H, Fomun Z T, Sterner O, Nielsen M & Witt M R, *Pharmacology*, 60, **2000**, 175.
- Wahe H, Mbafor J T, Nkengfack A E, Fomun Z T, Cherkasov R A, Sterner O & Doepp D, *ARKIVOC*, 15, **2003**, 107-114.
- Muller H, Kassack M U & Wiese M, *J Biomol Screen* 9(6), **2004**, 506.
- Baheti K G, Kapratwar S B & Kuberkar S V, *Synth Commun*, 32(14), **2002**, 2237.
- Metwally M A, Desoky E I, Fawzy R & Etman H A, *Chem of Heterocycl Compds*, 43(3), **2007**, 469.
- Fomun Z T, Asobo P F & Ifeadike P N, *J Heterocycl Chem*, 21, **1984**, 1125.
- Fomun Z T & Ifeadike P N, *J Heterocycl Chem*, 22, **1985**, 1611.
- Chan C K, Ma J C N & Mak T C W, *J Chem Soc, Perkin Trans 2*, **1977**, 1070.
- Asobo P F, Wahe H, Mbafor J T, Nkengfack A E, Fomun Z T, Sobue E F & Doepp D, *J Chem Soc, Perkin Trans 1*, **2001**, 457.